Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5195685 | 0.84 | CYP1A2 (0.47) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL5194046 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL5195674 | 0.81 | XDH (0.62) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL28245757 | 0.77 | RAB9A (0.56) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL28246572 | 0.76 | RAB9A (0.61) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL3831660 | 0.75 | CYP1A2 (0.53) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL2252377 | 0.75 | PTPN1 (0.55) | RAB9AKDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL4485015 | 0.72 | CDC7 (0.71) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL5551093 | 0.71 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AKDM4EPOLB | |
| SCHEMBL5193171 | 0.71 | DHODH (0.52) | SMN1; SMN2NPC1RAB9AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1321463-B1 | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC (CA) | 2007-08-08 | — | — | EP | claimed |
| US-6936629-B2 | Compounds and methods for the treatment or prevention of flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-08-30 | — | — | US | claimed |
| US-20030199503-A1 | Compounds and methods for the treatment of prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-10-23 | — | — | US | claimed |
| EP-1321463-A1 | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections | Shire Biochem Inc. (CA) | 2003-06-25 | — | — | EP | claimed |
| EP-1321463-B1 | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC (CA) | 2007-08-08 | — | — | EP | disclosed |
| US-6936629-B2 | Compounds and methods for the treatment or prevention of flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-08-30 | — | — | US | disclosed |
| US-20030199503-A1 | Compounds and methods for the treatment of prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-10-23 | — | — | US | disclosed |
| EP-1321463-A1 | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections | Shire Biochem Inc. (CA) | 2003-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199503-A1 | Compounds and methods for the treatment of prevention of flavivirus infections | HAVCR2, ZC3HAV1, EIF2AK2 | SMN1; SMN2 669/4885NPC1 11/4885RAB9A 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.